FGEN Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
FibroGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.23 |
| 52 Week High | US$19.47 |
| 52 Week Low | US$0.33 |
| Beta | 0.88 |
| 1 Month Change | 7.89% |
| 3 Month Change | -34.92% |
| 1 Year Change | -92.76% |
| 3 Year Change | -94.10% |
| 5 Year Change | -96.54% |
| Change since IPO | -94.41% |
Recent News & Updates
Recent updates
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
May 07
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Mar 22There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
Feb 05FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%
Dec 22A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)
Nov 24Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)
Apr 18Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts
Nov 12Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
Aug 26FibroGen Q2 2022 Earnings Preview
Aug 05Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Mar 31Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook
Mar 05Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?
Dec 08News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat
Aug 12Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term
Jul 17Is FibroGen A Buy Going Into Roxa AdCom?
Jul 13FibroGen in pact for three HiFiBiO programs in cancer and autoimmune disease
Jun 17Shareholder Returns
| FGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | 0.7% | 1.2% |
| 1Y | -92.8% | 5.0% | 27.7% |
Return vs Industry: FGEN underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: FGEN underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| FGEN volatility | |
|---|---|
| FGEN Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FGEN's share price has been volatile over the past 3 months.
Volatility Over Time: FGEN's weekly volatility has decreased from 24% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 486 | Thane Wettig | www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. Fundamentals Summary
| FGEN fundamental statistics | |
|---|---|
| Market cap | US$118.38m |
| Earnings (TTM) | -US$240.46m |
| Revenue (TTM) | US$167.49m |
0.7x
P/S Ratio-0.5x
P/E RatioIs FGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FGEN income statement (TTM) | |
|---|---|
| Revenue | US$167.49m |
| Cost of Revenue | US$295.51m |
| Gross Profit | -US$128.01m |
| Other Expenses | US$112.45m |
| Earnings | -US$240.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.42 |
| Gross Margin | -76.43% |
| Net Profit Margin | -143.56% |
| Debt/Equity Ratio | -48.2% |
How did FGEN perform over the long term?
See historical performance and comparison